Sarepta Therapeutics Announces Plan to Submit a New Drug Application (NDA) for Accelerated Approval of Golodirsen (SRP-4053) in Patients with Duchenne Muscular Dystrophy (DMD) Amenable to Skipping Exon 53

World News: . []

-- The Company met with the FDA Division of Neurology Products in February to obtain guidance on the regulatory pathway for golodirsen ---- The Company intends to complete a rolling NDA submission for golodirsen by year-end 2018 --CAMBRIDGE Mass March ...

More news and information about Sarepta Therapeutics, Inc.

Published By:

Globe Newswire: 11:30 GMT Monday 12th March 2018

Published: .

Search for other references to "sarepta" on SPi News


Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
Privacy Policy | Terms and Conditions | Contact Us